Berenberg cuts Novo Nordisk target as Eli Lilly's obesity lead curtails upside
Berenberg analysts lowered their price target for Novo Nordisk, citing Eli Lilly's dominant position in the obesity drug market as a constraint on Novo's growth prospects.
PA
Priya Anand · Equities & Earnings Desk · 13 Aug 2026 · 1 min read
Berenberg has reduced its valuation for Danish pharmaceutical group Novo Nordisk, citing concerns that the company's upside in the obesity segment may be limited by competitive pressures.
The brokerage points to Eli Lilly's dominant position in obesity therapeutics, which it says could restrict Novo Nordisk's ability to expand its own obesity portfolio and sustain growth in that market.
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →